関節リウマチ |
EULAR より |
EULAR Recommendations (一覧) |
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update |
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases |
2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases |
2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases |
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update |
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome |
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19 |
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis |
2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis |
EULAR recommendations for intra-articular therapies |
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19 |
EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis |
EULAR definition of difficult-to-treat rheumatoid arthritis |
EULAR Points to Consider for the assessment of competences in rheumatology specialty training |
ACR より |
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis |
2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures |
日本リウマチ学会 より |
関節リウマチ(RA)に対するTNF阻害薬使用の手引き (2020.2.1) |
関節リウマチ(RA)に対するIL-6阻害薬使用の手引き (2020.2.1) |
関節リウマチ(RA)に対するアバタセプト使用の手引き (2020.2.1) |
全例市販後調査のためのトファシチニブ適正使用ガイド(2020.2.1) |
全例市販後調査のためのバリシチニブ適正使用ガイド (2020.2.1) |
全例市販後調査のためのペフィシチニブ適正使用ガイド (2020.2.1) |
全例市販後調査のためのウパダシチニブ適正使用ガイド (2020.6.14) |
全例市販後調査のためのフィルゴチニブ使用ガイド (2020.12.4) |
関節リウマチ診療ガイドライン2020 (2021.4.26) |
関節リウマチに対するデノスマブ使用の手引き(2020.2.1) |
HTLV-1陽性関節リウマチ患者診療の手引(Q&A)第2版 厚労省研究班 2019年3月12日 |
関節リウマチ診療ガイドラインJCR2014に基づく一般医向け診療ガイドライン(2017.7.10) |
関節リウマチ治療におけるメトトレキサート(MTX)診療ガイドライン2016年改訂版 |
乾癬性関節炎 |
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update(EULAR) |
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis(ACR) |
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021(GRAPPA) |
乾癬性関節炎診療ガイドライン 2019(日本皮膚科学会) |
乾癬性関節炎(関節症性乾癬、PsA)、強直性脊椎炎(AS)および X線基準を満たさない体軸性脊椎関節炎(nr-axSpA)に対するインターロイキン(IL)-17阻害薬使用の手引き(日本リウマチ学会) |
乾癬性関節炎(関節症性乾癬、PsA)および強直性脊椎炎(AS)に対するTNF阻害薬使用の手引き(日本リウマチ学会)) |
乾癬性関節炎(関節症性乾癬、PsA)に対するIL-12/23阻害薬およびIL-23阻害薬使用の手引き(日本リウマチ学会) |
脊椎関節炎 |
EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice(EULAR) |
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis(EULAR) |
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis(ACR) |
ACR/SAA/SPARTAN 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis(ACR) |
強直性脊椎炎(AS)に対するTNF阻害療法施行ガイドライン (2010年10月改訂版)(日本リウマチ学会) |
乾癬性関節炎(関節症性乾癬、PsA)、強直性脊椎炎(AS)および X線基準を満たさない体軸性脊椎関節炎(nr-axSpA)に対するインターロイキン(IL)-17阻害薬使用の手引き(日本リウマチ学会) |
乾癬性関節炎(関節症性乾癬、PsA)および強直性脊椎炎(AS)に対するTNF阻害薬使用の手引き(日本リウマチ学会) |
脊椎関節炎診療の手引き2020(日本脊椎関節炎学会) |
掌蹠膿疱症性骨関節炎診療の手引き2022(日本脊椎関節炎学会) |
リウマチ性多発筋痛症 |
2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative(EULAR) |
2015 Recommendations for Management of Polymyalgia Rheumatica(ACR) |
痛風 |
2020 American College of Rheumatology Guideline for the Management of Gout(ACR) |
2016 updated EULAR evidence-based recommendations for the management of gout(EULAR) |
高尿酸血症・痛風の治療ガイドライン 第3版(日本痛風・尿酸核酸学会) |
成人スチル病 |
成人スチル病診療ガイドライン2017年版(厚生労働省 難治性疾患克服研究事業) |
全身性エリテマトーデス |
New: 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus(EULAR) |
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome(EULAR) |
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome(EULAR) |
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs(EULAR) |
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis(EULAR) |
2019 Update of the Joint European League Against Rheumatism and European Renal Association - European Dialysis and Transplant Association (EULAR/ER-EDTA) recommendations for the management of lupus nephritis(EULAR) |
New: EULAR recommendations for the management of antiphospholipid syndrome in adults(EULAR) |
American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis(ACR) |
ループス腎炎に対するリツキシマブ(遺伝子組換え)使用に関するステートメント(2022.2.21)(日本リウマチ学会) |
全例市販後調査のためのアニフロルマブ適正使用の手引き(2021.11.22)(日本リウマチ学会) |
全身性エリテマトーデス(SLE)の診療ガイドライン(2019.5.14)(日本リウマチ学会) |
市販後調査のためのベリムマブ適正使用ガイドライン (2017.11.30)(日本リウマチ学会) |
皮膚エリテマトーデスおよび全身性エリテマトーデスに対するヒドロキシクロロキン使用のための簡易ガイドライン(日本リウマチ学会) |
ヒドロキシクロロキン適正使用の手引き(日本皮膚科学会) |
S2k guideline for treatment of cutaneous lupus erythematosus - guided by European Dermatology Forum (EDF) in cooperation with the EADV(欧州皮膚性病学会) |
S2k - European Dermatology Forum Guideline on Dianosis and Monitoring in Cutaneous Lupus Erytematosus(欧州皮膚科学フォーラム) |
S2k - European Dermatology Forum Guideline for the Treatment of Cutaneous Lupus Erytematosus(欧州皮膚科学フォーラム) |
抗リン脂質抗体症候群 |
EULAR recommendations for the management of antiphospholipid syndrome in adults(EULAR) |
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome(EULAR) |
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome(EULAR) |
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs(EULAR) |
2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases(ACR) |
Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis(国際血栓止血学会) |
抗リン脂質抗体症候群・好酸球性多発血管炎性肉芽腫症・結節性多発動脈炎・リウマトイド血管炎の治療の手引き 2020 (厚生労働省 難治性疾患克服研究事業) |
抗リン脂質抗体症候群合併妊娠の診療ガイドライン(日本母性内科学会) |
Immune thrombocytopenia (ITP) |
American Society of Hematology 2019 guidelines for immune thrombocytopenia(American Society of Hematology) |
全身性強皮症 |
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)(EULAR) |
Update of EULAR recommendations for the treatment of systemic sclerosis(EULAR) |
全身性強皮症診療ガイドライン(日本皮膚科学会) |
診断基準・重症度分類・診療ガイドライン(日本皮膚科学会) |
S1-Guideline on the Diagnosis and Treatment of Sclerosing Diseases of the Skin(欧州皮膚科学フォーラム) |
特発性炎症性筋疾患(皮膚筋炎/多発筋炎) |
多発性筋炎・皮膚筋炎診療ガイドライン(2020 年暫定版)(厚生労働省難治性疾患克服研究事業) |
混合性結合組織病 |
MCTD(混合性結合組織病)診療ガイドライン2021(厚生労働省難治性疾患克服研究事業) |
シェーグレン症候群 |
シェーグレン症候群診療ガイドライン2017年版(厚生労働省難治性疾患克服研究事業) |
EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies(EULAR) |
IgG4関連疾患 |
International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease(International symposium on IgG4-Related disease) |
血管炎 |
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Treatment and Management of ANCA-Associated Vasculitis(ACR) |
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis(ACR) |
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa(ACR) |
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease(ACR) |
EULAR Recommendations for the use of imaging in large vessel vasculitis in clinical practice(EULAR) |
2018 Update of the EULAR recommendations for the management of large vessel vasculitis(EULAR) |
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis(EULAR) |
ANCA関連血管炎診療ガイドライン2017(2017年改訂版) 厚労省研究班 2017年2月7日(厚生労働省 難治性疾患克服研究事業) |
血管炎症候群の診療ガイドライン(2017年改訂版)厚労省研究班 2018年3月23日(合同研究班(循環器学会、リウマチ学会など) |
血管炎・血管障害診療ガイドライン2016年改訂版(日本皮膚科学会) |
市販後調査のためのメポリズマブ適正使用の手引き (2020.2.1)(日本リウマチ学会) |
ベーチェット病 |
ベーチェット病診療ガイドライン2020(厚生労働省難治性疾患克服研究事業/日本ベーチェット病学会) |
2018 update of the EULAR Recommendations for the management of Behçet's syndrome(日本皮膚科学会) |
リウマチ性疾患におけるCOVID-19 |
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update(EULAR) |
COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases (RMDs)(ACR) |
Clinical Guidance for Adult Patients with Rheumatic Diseases(ACR) |
Clinical Guidance for Pediatric Patients(ACR) |
ACR Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 2(ACR) |
Clinical Guidance Summary for Pediatric Patients with MIS-C Associated with SARS-CoV-2 and Hyperinflammation in COVID-19(ACR) |
ACR Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS‐C) Associated with SARS‐CoV‐2 and Hyperinflammation in COVID‐19. Version 3(ACR) |